← Alle mensen

RC

Raffaele Califano

12 publicaties

PubMed → Google Scholar →

Publicaties op Oncologisch.com

EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated e...
European journal of cancer (Oxford, England : 1990) · 9 december 2025
Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Fase III IPSOS Study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025-12
Totale overleving with Amivantamab-Lazertinib in EGFR-Mutated Gevorderd NSCLC.
The New England journal of medicine · 30 oktober 2025
Efficacy and safety of eerstelijns maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-...
Lancet (London, England) · 14 juni 2025
Amivantamab plus lazertinib als eerstelijns bij EGFR-gemuteerd NSCLC: MARIPOSA fase III definitief
The New England journal of medicine · 24 oktober 2024
Eerstelijns atezolizumab mono versus chemotherapie bij NSCLC: IMpower110 langetermijn
Lancet (London, England) · 5 augustus 2023
Brigatinib versus crizotinib bij ALK-positief NSCLC: ALTA-1L definitieve resultaten
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021-12
Nivolumab versus placebo bij recidief mesothelioom: CONFIRM fase III
The Lancet. Oncology · 2021-11
Pembrolizumab plus ipilimumab of placebo bij PD-L1≥50% NSCLC: KEYNOTE-598 fase III
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 juli 2021
Geactualiseerde OS en PD-L1 subanalyse bij uitgebreid SCLC: CASPIAN update
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 februari 2021
Brigatinib versus crizotinib bij ALK-positief NSCLC: ALTA-1L definitieve PFS
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 november 2020
Brigatinib versus crizotinib bij ALK-positief NSCLC: ALTA-1L fase III
The New England journal of medicine · 22 november 2018